GSK stock gets a GBp 2,200.00 target from Berenberg

Published on 09/29/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Berenberg shifted GSK from Hold to Buy and raised its target to GBp 2,200.00 on September 15, 2026. Q2 sales reached GBP 8.40 billion.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock has a new GBp 2,200.00 price target after Berenberg upgraded the shares from Hold to Buy on September 15, 2026. The rating change followed a series of pipeline investments, including a potential GBP 750.00 million agreement for a trispecific T-cell engager.

Berenberg backs pipeline spending

According to Yahoo Finance on September 24, 2026, analyst Kerry Holford lifted Berenberg's target from GBp 2,000.00 to GBp 2,200.00 and changed the recommendation to Buy. The report linked the more positive view to GSK's business-development activity and pipeline momentum.

The Chimagen agreement covers global rights to a trispecific T-cell engager for multiple myeloma, with total payments potentially reaching GBP 750.00 million. The program is expected to enter Phase I trials in 2027, so the commercial value remains dependent on clinical progress.

Q2 sales rose 5.00 percent

GSK's second-quarter 2026 sales reached GBP 8.40 billion, up 5.00 percent at both actual exchange rates and constant exchange rates, according to TipRanks in its September 8, 2026 report on the July 28 results. GSK also reported 62 clinical assets and plans to start more than 20 Phase III trials in 2026, compared with a prior plan of 10.

The company is pairing that pipeline expansion with a three-year program targeting GBP 1.90 billion in annual savings by 2029. TipRanks also reported a Q2 2026 dividend of GBp 17.00 per share, showing that capital allocation continues alongside research investment.

LSE quote sits below yearly high

GSK traded at GBp 1,895.50 on the London Stock Exchange on September 29, 2026. The same quote showed a 52-week range of GBp 1,590.50 to GBp 2,282.00, placing the stock 16.94 percent below its yearly high.

The central investor question is execution: Berenberg's thesis depends on pipeline additions becoming approved medicines, while GSK's latest operating figures show that current sales growth is already measurable. The next quarterly update is listed for October 28, 2026.